TAS-108, a novel oral steroidal antiestrogenic agent, is a pure antagonist on estrogen receptor α and a partial agonist on estrogen receptor β with low uterotrophic effect

Clinical Cancer Research

Volumn 11, Issue 1, 2005, Pages 315-322

  Yamamoto, Yasuji ^a   Shibata, Jiro ^a   Yonekura, Kazuhiko ^a   Sato, Kouji ^a   Hashimoto, Akihiro ^a   Aoyagi, Yoshimi ^a   Wierzba, Konstanty ^a   Yano, Shingo ^a   Asao, Tetsuji ^a   Buzdar, Aman U ^b   Terada, Tadafumi ^a  

^a TAIHO PHARMACEUTICAL CO LTD   (Japan)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

21 (4 DIETHYLAMINOMETHYL 2 METHOXYPHENOXY) 7ALPHA METHYL 19 NORPREGNA 1,3,5(10) TRIEN 3 OL; ANTIESTROGEN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FULVESTRANT; RALOXIFENE; TAMOXIFEN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER INHIBITION; CONTROLLED STUDY; DRUG INHIBITION; DRUG SCREENING; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSACTIVATION; TUMOR GROWTH; TUMOR MODEL;

9,10-DIMETHYL-1,2-BENZANTHRACENE; ADMINISTRATION, ORAL; ANIMALS; CARCINOGENS; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; ESTROGEN RECEPTOR MODULATORS; FEMALE; GENES, REPORTER; HUMANS; LUCIFERASES; MICE; MICE, NUDE; MODELS, CHEMICAL; NEOPLASM TRANSPLANTATION; OVARY; PROTEIN BINDING; RALOXIFENE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ESTROGEN; TAMOXIFEN; TIME FACTORS; TRANS-ACTIVATION (GENETICS); TREATMENT OUTCOME; UTERUS;

EID: 19944427846     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Jemal A, Murray T, Samuels A, et al. Cancer statistics, 2003. CA Cancer J Clin 2003;53:5-26.
2. Jaiyesimi IA, Buzdar AU, Decker DA, Hortobagyi GN. Use of tamoxifen for breast cancer: twenty-eight years later. J Clin Oncol 1995;13:513-29.
3. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 1998;351:1451-67.
4. McDonnell DP, Clemm DL, Hermann T, Goldman ME, Pike JW. Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens. Mol Endocrinol 1995;9:659-69.
5. Love RR, Mazess RB, Barden HS, et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 1992;326:852-6.
6. Kauffman RF, Bryant HU. Selective estrogen receptor modulators. Drug News Perspect 1995;8:531-9.
7. Frolik CA, Bryant HU, Black EC, Magee DE, Chandrasekhar S. Time-dependent changes in biochemical bone markers and serum cholesterol in ovariectomized rats: effects of raloxifene HCl, tamoxifen, estrogen, and alendronate. Bone 1996;18:621-7.
8. Kedar RP, Bourne TH, Powles TJ, et al. Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial. Lancet 1994;343:1318-21.
9. Fisher B, Costantino JP, Redmond CK, et al. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 1994;86:527-37.
10. Baum M. Tamoxifen and the breast. Eur J Cancer 1998;34:S7-8.
11. Heringa M. Review on raloxifene: profile of a selective estrogen receptor modulator. Int J Clin Pharmacol Ther 2003;41:331-45.
12. Black LJ, Sato M, Rowley ER, et al. Raloxifene (LY139481 HCl) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. J Clin Invest 1994;93:63-9.
13. Buzdar AU, Marcus C, Holmes F, Hug V, Hortobagyi G. Phase II evaluation of Ly156758 in metastatic breast cancer. Oncology 1988;45:344-5.
14. Gradishar WJ, Jordan VC. Clinical potential of new antiestrogens. J Clin Oncol 1997;15:840-52.
15. Barker S. Anti-estrogens in the treatment of breast cancer: current status and future directions. Curr Opin Investig Drugs 2003;4:652-7.
16. Nabholtz JM, Bonneterre J, Buzdar A, Robertson JF, Thurlimann B. Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results. Eur J Cancer 2003;39:1684-9.
17. Mouridsen H, Gershanovich M, Sun Y, et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol 2003;21:2101-9.
18. Bross PF, Baird A, Chen G, et al. Fulvestrant in postmenopausal women with advanced breast cancer. Clin Cancer Res 2003;9:4309-17.
19. Meegan MJ, Lloyd DG. Advances in the science of estrogen receptor modulation. Curr Med Chem 2003;10:181-210.
20. Wieder R, Shimkin M. An improved method of producing hormone-cholesterol pellets. J Natl Cancer Inst 1964;32:957-8.
21. Saotome K, Morita H, Umeda M. Cytotoxicity test with simplified crystal violet staining method using microtitre plates and its application to injection drugs. Toxicol In Vitro 1989;3:317-21.
22. Tora L, Mullick A, Metzger D, et al. The cloned human oestrogen receptor contains a mutation which alters its hormone binding properties. EMBO J 1989;8:1981-6.
23. Watanabe M, Yanagisawa J, Kitagawa H, et al. A subfamily of RNA-binding DEAD-box proteins acts as an estrogen receptor a coactivator through the N-terminal activation domain (AF-1) with an RNA coactivator, SRA. EMBO J 2001;20:1-12.
24. Yanagisawa J, Yanagi Y, Masuhiro Y, et al. Convergence of transforming growth factor-β and vitamin D signaling pathways on SMAD transcriptional coactivators. Science 1999;283:1317-21.
25. Yamamoto Y, Wada O, Takada I, et al. Both N- and C-terminal transactivation functions of DNA-bound ERα are blocked by a novel synthetic estrogen ligand. Biochem Biophys Res Commun 2003;312:656-62.
26. Toko T, Shibata J, Sugimoto Y, et al. Comparative pharmacodynamic analysis of TAT-59 and tamoxifen in rats bearing DMBA-induced mammary carcinoma. Cancer Chemother Pharmacol 1995;37:7-13.
27. Huggins C, Grand LC, Brillantes FP. Mammary cancer induced by a single feeding of polymucular hydrocarbons, and its suppression. Nature 1961;189:204-7.
28. Kato S. Estrogen receptor-mediated cross-talk with growth factor signaling pathways. Breast Cancer 2001;8:3-9.
29. Warnmark A, Treuter E, Wright AP, Gustafsson JA. Activation functions 1 and 2 of nuclear receptors: molecular strategies for transcriptional activation. Mol Endocrinol 2003;17:1901-9.
30. Furr BJ, Jordan VC. The pharmacology and clinical uses of tamoxifen. Pharmacol Ther 1984;25:127-205.
31. Yamamoto Y, Wada O, Suzawa M, et al. The tamoxifen-responsive estrogen receptor α mutant D351Y shows reduced tamoxifen-dependent interaction with corepressor complexes. J Biol Chem 2001;276:42684-91.
32. Blakely LJ, Buzdar A, Chang HY, et al. A phase I and pharmacokinetic study of TAS-108 in postmenopausal female patients with locally advanced, locally recurrent inoperable, or progressive metastatic breast cancer. Clin Cancer Res 2004;10:5425-31.
33. Speirs V, Carder PJ, Lane S, et al. Oestrogen receptor β: what it means for patients with breast cancer. Lancet Oncol 2004;5:174-81.
34. Weihua Z, Andersson S, Cheng G, et al. Update on estrogen signaling. FEBS Lett 2003;546:17-24.
35. Gustafsson JA. Estrogen receptor β - a new dimension in estrogen mechanism of action. J Endocrinol 1999;163:379-83.
36. Lindberg MK, Weihua Z, Andersson N, et al. Estrogen receptor specificity for the effects of estrogen in ovariectomized mice. J Endocrinol 2002;174:167-78.
37. Seidlova-Wuttke D, Becker T, Christoffel V, Jarry H, Wuttke W. Silymarin is a selective estrogen receptor beta (ERβ) agonist and has estrogenic effects in the metaphysis of the femur but no or antiestrogenic effects in the uterus of ovariectomized (ovx) rats. J Steroid Biochem Mol Biol 2003;86:179-88.
38. Lindberg MK, Moverare S, Skrtic S, et al. Estrogen receptor (ER)-β reduces ERα-regulated gene transcription, supporting a "ying yang" relationship between ERα and ERβ in mice. Mol Endocrinol 2003;17:203-8.
39. Iwao K, Miyoshi Y, Egawa C, Ikeda N, Noguchi S. Quantitative analysis of estrogen receptor-β mRNA and its variants in human breast cancers. Int J Cancer 2000;88:733-6.
40. Albertazzi P. Purified phytoestrogens in postmenopausal bone health: is there a role for genistein? Climacteric 2002;5:190-6.
41. Barkhem T, Carlsson B, Nilsson Y, et al. Differential response of estrogen receptor α and estrogen receptor β to partial estrogen agonists/antagonists. Mol Pharmacol 1998;54:105-12.
42. Jones SE. Fulvestrant: an estrogen receptor antagonist that down-regulates the estrogen receptor. Semin Oncol 2003;30:14-20.
43. Sturgeon SR, Potischman N, Malone KE, et al. Serum levels of sex hormones and breast cancer risk in premenopausal women: a case-control study (USA). Cancer Causes Control 2004;15:45-53.
44. Endogenous Hormones and Breast Cancer Collaborative Group. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 2002;94:606-16.
45. Shafie SM, Grantham FH. Role of hormones in the growth and regression of human breast cancer cells (MCF-7) transplanted into athymic nude mice. J Natl Cancer Inst 1981;67:51-6.
46. Finkelman RD, Bell NH, Strong DD, Demers LM, Baylink DJ. Ovariectomy selectively reduces the concentration of transforming growth factor beta in rat bone: implications for estrogen deficiency-associated bone loss. Proc Natl Acad Sci U S A 1992;89:12190-3.